Consun Pharmaceutical Group Limited (HKG:1681)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
17.39
+0.89 (5.39%)
At close: Mar 27, 2026
Market Cap14.63B +126.9%
Revenue (ttm)3.80B +15.2%
Net Income1.20B +18.4%
EPS1.40 +15.6%
Shares Out841.32M
PE Ratio12.40
Forward PE10.40
Dividend0.66 (3.80%)
Ex-Dividend DateJun 9, 2026
Volume3,180,498
Average Volume2,464,800
Open16.50
Previous Close16.50
Day's Range16.41 - 17.56
52-Week Range8.23 - 19.49
Beta0.57
RSI53.59
Earnings DateMar 26, 2026

About HKG:1681

Consun Pharmaceutical Group Limited researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People’s Republic of China. It operates in two segments, Consun Pharmaceutical and Yulin Pharmaceutical. The company offers uremic clearance granule to treat chronic kidney diseases; Yishen Huashi particles for proteinuria; TCM to treat diabetic kidney disease; Gadopentetate Dimeglumine injections for nervous centralis, stomach, chest, pelvic cavity, and extremities, as well as for renal function ass... [Read more]

Sector Healthcare
Founded 1997
Employees 3,073
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 1681
Full Company Profile

Financial Performance

In 2025, HKG:1681's revenue was 3.42 billion, an increase of 15.17% compared to the previous year's 2.97 billion. Earnings were 1.08 billion, an increase of 18.41%.

Financial numbers in CNY Financial Statements